Key Takeaways
- Biohaven’s troriluzole has failed a phase 3 trial in obsessive-compulsive disorder (OCD).
- The company will cease development of troriluzole for OCD to focus on other programs.
- The FDA is reconsidering the drug for a rare disease, with a decision expected in Q4 2025.
Recent Developments on Troriluzole
Biohaven Pharmaceuticals has encountered significant setbacks with its drug, troriluzole. The FDA’s recent decision to convene an advisory committee regarding the drug’s potential approval for a rare disease has resulted in a pushed PDUFA date to the fourth quarter of 2025. Compounding these challenges, the drug has now failed a phase 3 clinical trial aimed at treating obsessive-compulsive disorder (OCD).
Following this latest trial failure, Biohaven has announced it will terminate the development of troriluzole for OCD, redirecting resources toward other projects within its pipeline. Insights garnered from the phase 3 trial results will be shared at an upcoming conference.
Troriluzole is a prodrug of riluzole, the latter being the first drug approved in 1995 for amyotrophic lateral sclerosis (ALS). However, the development history of troriluzole has been marked by a series of clinical trial failures. Previous attempts at demonstrating efficacy in OCD were unsuccessful; the drug did not meet the primary outcome in a 2020 phase 2/3 trial. Further setbacks include a 2021 failure in a phase 2/3 trial for Alzheimer’s disease and an unsuccessful first phase 3 trial in spinocerebellar ataxia, the condition for which it is currently under reconsideration by the FDA.
Despite these challenges, a glimmer of hope arose earlier this year when a second phase 3 test hinted at the drug’s potential to significantly slow disease progression for the rare condition it is currently under review for. After previously declining to review the asset in 2023, the FDA has determined to give it another chance based on these results.
Biohaven’s latest announcements underscore their strategic pivot in light of the ongoing challenges facing troriluzole. The future of the drug will now hinge on the forthcoming advisory committee’s assessment and the organization’s ability to successfully navigate the complexities of drug development in the face of adversity.
The content above is a summary. For more details, see the source article.